Abstract
The aim of the study was to determine the influence of pre-symptomatic and symptomatic stages of Parkinson’s disease and its treatment on the cardiac disorders in C57BL/6 mice. Materials and methods. Investigations were carried out on C57BL/6 male mice. Degeneration of dopaminergic neurons were created by the neurotoxin. In freely moving animals in online regime a 24-hour ECG recording using wireless telemetry system ML880B106 was conducted. After completing studies animals was injected L-dopa (a precursor of dopamine synthesis). All the animals underwent repeated study of HRV. Results. The disbalance of autonomic heart regulation develops already in the pre-symptomatic stage of Parkinson’s disease. The early symptomatic stage is accompanied by the aggravation of heart dysfunction due to the shift of the autonomic balance towards the increase of sympathetic and decrease of parasympathic effect on the heart. Coronary disorders concomitant to Parkinson’s disease increase a risk of life threatening arrhythmia and sudden death syndrome not only in the early symptomatic stage but also in the pre-symptomatic stage. Conclusions. L-dopa effectively restores the structure of heart rate and prevents the risk of life threatening arrhythmia only in the pre-symptomatic stage of disease.
Highlights
Parkinson’s disease (PD) is one of the most wide spread, slowly progressing diseases determined by progressive degeneration of dopaminergic neurons of nigrostriatal system
To simulate early symptomatic stage (ESS), the same dose of neurotoxin was injected for 12 animals 4 times
In modeling the severe stage (SS) of dopaminergic neurons of the nigrostriatal system (DNNS), MPTP was administered at a dose of 18 mg/kg for 15 animals four times, at intervals of 2 hours (9)
Summary
Parkinson’s disease (PD) is one of the most wide spread, slowly progressing diseases determined by progressive degeneration of dopaminergic neurons of nigrostriatal system. These changes affects the brainstem nuclei and higher vegetative centers. They determine vegetative-visceral dysfunctions, especially by disturbing regulation of the cardiovascular system (1-3). Many cases of sudden cardiac death are reported in patients diagnosed with Parkinson’s disease (4). Treatment of neurological symptoms in such patients without taking into consideration the cardiovascular system disorders can lead to cardiac dysfunction. It is known that the treatment of these patients using dopamine agonists increases the risk of cardiac failure (5,6)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
